Abstract: The present invention relates to tertiary 4-amino-2-ureidopyrimidine-5-carboxamides of formula I: ##STR1## in which R.sup.1 is (C.sub.1 -C.sub.8)-alkyl wherein one or more H are replaced by F; R.sup.2 is selected from the group consisting of F, Cl, Br, H, --O--(C.sub.1 -C.sub.8)-alkyl and (C.sub.1 -C.sub.8)-alkyl, wherein one or more of the H of the alkyls can be replaced by F; R.sup.3 is selected from the group consisting of F, Cl, Br, H, --O--(C.sub.1 -C.sub.4)-alkyl and (C.sub.1 -C.sub.4)-alkyl, wherein one or more of the H of the alkyl can be replaced by F; R.sup.4 is CF.sub.3 or OCF.sub.3 ; and their physiologically tolerable salts. Process for preparing the compounds of formula I are also described. The compounds are suitable for the treatment of disorders of lipid metabolism.

Abstract: Compounds of the formula I ##STR1## in which R.sup.1 to R.sup.6 have the stated meanings, and the readily water-soluble salts of these compounds, and a process for the preparation thereof are described. The compounds are suitable for the treatment of lipid metabolism disorders which are beneficially influenced by a stimulation of the hepatic LDL receptor.Also described are compounds of the formula II ##STR2## and the salts thereof.

Abstract: The invention relates to compounds of the formula ##STR1## in which R.sup.1 and R.sup.2 are identical or different and are hydrogen, alkyl, trifluoromethyl, halogen, alkoxycarbonyl, alkoxy or alkanoyl, R.sup.3, R.sup.4 and R.sup.5 are identical or different and are hydrogen, methyl, alkoxy or alkoxyethoxy, and R is hydrogen or a group SR.sup.6, in which R.sup.6 is the lone, unpaired electron of the 12-sulfenyl radical, hydrogen, optionally substituted alkyl, alkenyl, alkynyl, alkanoyl, optionally mono- or poly-substituted benzoyl, fuoryl, phenacyl, phenoxyacetyl, phenylacetyl or another conventional thiol-protective group, and to physiologically acceptable salts thereof, and to processes for their preparation, to their use as a gastric acid secretion inhibitor and to pharmaceutical preparations based on these compounds.

Abstract: 8-Aryl-5,6,7,8-tetrahydropyrazolo(3,4-b)(1,4)diazepine-1H,4H-5,7-diones of the formula ##STR1## in which R.sub.1 through R.sub.5 are as defined in the specification, and medicaments containing these having an anxiolytic action.

Abstract: Compound of the general formula ##STR1## in which R.sub.1 and R.sub.2 are identical or different and represent hydrogen atoms or alkyl groups with 1-6 C atoms, it also being possible for one of the radicals R.sub.1 and R.sub.2 to be, in each case, a benzyl, trifluoromethyl or phenyl group, R.sub.3 denotes a hydrogen atom, an alkyl group which has 1-6 C atoms and is optionally substituted by an aryl group, an alkoxy group with 1-6 C atoms, a trifluoromethyl group, a dialkylamino group with 2-12 C atoms or a cycloalkyl group with 3-6 C atoms, an alkenyl or alkynyl group with 2-6 C atoms, a cycloalkyl group with 3-6 C atoms or a carbalkoxy group with 2-6 C atoms, R.sub.4 is a hydrogen atom and R.sub.5 can be a phenyl group, a phenyl group which is monosubstituted or disubstituted by methyl Cl, Br, F, nitro, cyano and or trifluoromethyl or a pyridyl group and medicaments containing same.